• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virol Sin . Antigenic Drift of the Hemagglutinin from an Influenza A (H1N1) pdm09 Clinical Isolate Increases its Pathogenicity In Vitro

tetano

Editor, Senior Moderator
Virol Sin


. 2021 Jun 9;1-8.
doi: 10.1007/s12250-021-00401-y. Online ahead of print.
Antigenic Drift of the Hemagglutinin from an Influenza A (H1N1) pdm09 Clinical Isolate Increases its Pathogenicity In Vitro


Lei Xing[SUP] #[/SUP][SUP] 1 2 [/SUP], Yunbo Chen[SUP] #[/SUP][SUP] 3 [/SUP], Boqian Chen[SUP] 3 [/SUP], Ling Bu[SUP] 1 2 [/SUP], Ying Liu[SUP] 4 [/SUP], Zhiqi Zeng[SUP] 1 [/SUP], Wenda Guan[SUP] 1 [/SUP], Qigao Chen[SUP] 1 [/SUP], Yongping Lin[SUP] 1 [/SUP], Kun Qin[SUP] 5 [/SUP], Honglin Chen[SUP] 6 [/SUP], Xilong Deng[SUP] 7 [/SUP], Xinhua Wang[SUP] 8 9 10 [/SUP], Wenjun Song[SUP] 11 12 13 [/SUP]



Affiliations
Free PMC article

Abstract

The influenza A (H1N1) pdm09 virus emerged in 2009 and has been continuously circulating in humans for over ten years. Here, we analyzed a clinical influenza A (H1N1) pdm09-infected patient case hospitalized for two months in Guangdong (from December 14, 2019 to February 15, 2020). This isolate, named A/Guangdong/LCF/2019 (LCF/19), was genetically sequenced, rescued by reverse genetics, and phylogenetically analyzed in the context of other relevant pdm09 isolates. Compared with earlier isolates, this pdm09 virus's genetic sequence contains four substitutions, S186P, T188I, D190A, and Q192E, of the hemagglutinin (HA) segment at position 186-192 (H3 numbering) in the epitope Sb, and two of which are located at the 190-helix. Phylogenetic analysis indicated that the epitope Sb started undergoing a rapid antigenic change in 2018. To characterize the pathogenicity of this novel substitution motif, a panel of reassortant viruses containing the LCF/2019 HA segment or the chimeric HA segment with the four substitutions were rescued. Kinetic growth data revealed that the reassortant viruses, including the LCF/2019 with the PTIAAQE substitution, propagated faster than those rescued ones having the STTADQQ motif in the epitope Sb in Madin-Darby Canine Kidney (MDCK) cells. The HI test showed that the binding activity of escape mutant to 2018 pdm09 sera was weaker than GLW/2018, suggesting that old vaccines might not effectively protect people from infection. Due to the difference in the selection of vaccine strains, people vaccinated in the southern hemisphere could still suffer a severe infection if infected with this antigenic drift pdm09 virus.

Keywords: HA antigenic drift; HA epitope Sb; Influenza A (H1N1) pdm09 virus.
 
Back
Top Bottom